Graham C, McGuire M, Knox H, Ung B. Budget impact analysis of enasidenib treatment in patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S31.
Krishnarajah G, Knox H, Graham CN, Christiansen S, Zuraw B. Subcutaneous C1-inhibitor prophylactic treatment for hereditary angioedema: a budget impact model. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S37.
Maglinte G, Graham C, Schwartzberg L, Price T, Knox H, Hechmati G, Hjelmgren J, Barber B, Fakih M. Economic analysis of panitumumab versus cetuximab in chemorefractory patients with wild-type KRAS metastatic colorectal cancer. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 9, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 21(4a):S11-2.